Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $326,520.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,721 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00. Following the completion of the sale, the senior vice president owned 3,114 shares in the company, valued at $373,680. The trade was a 46.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM traded up $5.13 during trading hours on Thursday, reaching $125.59. 653,000 shares of the company’s stock were exchanged, compared to its average volume of 936,409. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $7.66 billion, a P/E ratio of -9.23 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 12 month low of $49.01 and a 12 month high of $125.75. The business’s 50-day simple moving average is $101.93 and its two-hundred day simple moving average is $95.13.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. During the same period in the prior year, the company posted ($0.30) EPS. Mirum Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. Sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $1,478,000. TD Asset Management Inc bought a new stake in Mirum Pharmaceuticals in the third quarter worth $1,129,000. Tudor Investment Corp ET AL acquired a new position in Mirum Pharmaceuticals during the third quarter worth $2,027,000. Nan Fung Trinity HK Ltd. increased its position in Mirum Pharmaceuticals by 45.6% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock worth $17,969,000 after buying an additional 71,214 shares during the last quarter. Finally, SBI Okasan Asset Management Co.Ltd. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at about $1,283,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on MIRM shares. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. JPMorgan Chase & Co. boosted their price objective on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday. TD Cowen upped their price objective on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $165.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $143.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.